Search
for

    Glossary5-alpha-reductase inhibitor

    blocks enzyme converting testosterone to dihydrotestosterone (DHT)

    A 5-alpha-reductase inhibitor is a type of medication that blocks the enzyme 5-alpha-reductase, which is responsible for converting testosterone into dihydrotestosterone (DHT). By reducing DHT levels, these inhibitors can help treat conditions like male pattern baldness and benign prostatic hyperplasia (BPH).

    Related Terms

    Learn

    5 / 5 results

      learn Finasteride

      Frontline, gold standard treatment for combatting androgenic alopecia

      learn Saw Palmetto

      a natural and far less effective alternative to Finasteride

      learn Azelaic Acid

      acid used for antimicrobial, anti-inflammatory and anti-androgenic properties

      learn Rosemary

      herb and oil with stimulant, circulatory, anti-inflammatory and antioxidant properties

    Research

    5 / 1000+ results

    Community Join

    5 / 254 results

      community Do these two supplements inhibit 5alpha-reductase?

      in Chat  1 upvotes 4 years ago
      Pumpkin Seed Oil and Perilla Oil (with alpha-lipoic acid, linoleic acid, and oleic acid) are discussed as potential 5alpha-reductase inhibitors. The conversation focuses on their effectiveness for hair loss treatment.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.